NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. Why was Elevance Sued for Securities Fraud? If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Elevance provides health i ...

Hims & Hers Health shares rocketed higher over the last year, rewarding investors. When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services. What does Oscar Health do, and why might it draw comparisons to Hims & Hers? When it comes to accessing patient care, consumers have a couple of optio ...

UnitedHealth Group (UNH 0.49%) is in the headlines again, this time, it's to announce that it is exiting Latin America. The announcement is just the latest in a series of news events in what has been a tumultuous year for the once-safe healthcare giant, whose shares are down a staggering 38% year to date as of June 13. There's been a flurry of bad news surrounding this business, including a change in its CEO last month. Does the company exiting Latin America signal more challenges ahead for the business, an ...

Key Takeaways UnitedHealth leans on Optum to offset pressures in its health benefits business. Optum's revenue growth outpaced UnitedHealthcare from 2022 to 2024. Optum contributed over half of UnitedHealth's total operating income last year.Yes, UnitedHealth Group Incorporated (UNH) is increasingly relying on its Optum business to drive growth and offset challenges in the health benefits segment, UnitedHealthcare. Optum has become the company’s primary growth engine, delivering stronger margins and faste ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of Elevance Health, Inc. common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Group 1: Class Action Details - Investors who purchased Elevance common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 11, 2025 [2]. - The lawsuit alleges that Elevance made false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has recovered hundreds of millions of dollars for investors and has been recognized for its performance in securities class action settlements [3]. - Investors have the option to select their counsel or remain absent from the class until it is certified [6].

Humana (HUM) 2025 Investor Day June 16, 2025 02:00 PM ET Speaker0 Ladies and gentlemen, welcome to Louisville, Kentucky for Humana's twenty twenty five Investor Day. Please welcome to the stage Lisa Stoner, Vice President of Investor Relations. Speaker1 Great. Good afternoon. Welcome to Humana's twenty twenty five Investor Conference. We really appreciate you all joining today. It is great to see so many familiar faces here in the room. And thank you to everyone that's joining us virtually. Over the next th ...

美国参议院（单独主张的）税收立法草案建议，将医疗保险供应商的税率下调至3.5%。（Politico） ...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly failing to disclose the impact of Medicaid redetermination on its business prospects, leading to significant financial misrepresentation [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Elevance Health misled investors by stating they were monitoring Medicaid cost trends and that their premium negotiations were sufficient, despite rising Medicaid expenses [2]. - The company acknowledged rising Medicaid expenses but assured investors that these were adequately reflected in their financial guidance, which was later proven inaccurate as the acuity and utilization of Medicaid members increased significantly [2]. - Following the company's admission of increased Medicaid utilization on July 17, 2024, Elevance's stock price dropped by $32.21 per share, or 5.8%, indicating a negative market reaction to the news [3]. Group 2: Class Action Participation - Shareholders interested in participating in the class action must file their papers by July 11, 2025, to serve as lead plaintiff, representing the interests of other class members [4]. - Shareholders are not required to participate in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation in the lawsuit [5].

Group 1 - The focus is on growth and dividend income, with a strategy aimed at creating a portfolio that emphasizes compounding dividend income and growth [1] - The portfolio is structured to provide monthly dividend income that increases through dividend reinvestment and annual raises [1] Group 2 - There is an intention to potentially start a position in OSCR in the near future [2] - The article serves as personal opinion and is not intended as a recommendation for stock purchase or sale [2] Group 3 - Past performance is not indicative of future results, and no specific investment advice is provided [3] - The views expressed may not represent those of Seeking Alpha as a whole, and the analysts may not be licensed or certified [3]